Loading today’s stories

Today

AI-assisted reporting, grounded in a per-article claim ledger. Perspective Coverage and Reality Strip separate source viewpoints from evidence, adoption, hype, incentives, and confidence.

Today

Front Page
Today’s Briefing
Newsletters
Trending
For You
Discover
My Stack
Saved
Off Radar
Search

Sections

Security
Build
Invest
Product
Leadership
Science

Company

About
Mission
How this is made
Evidence Index
The desks
The sources we read
Corrections
Press and brand
The daily edition

Trending now

H-1B Visa Policy
Israeli Tech Ecosystem
Agentic AI Risk
Teen online safety
Local-first AI agents
AI Copyright Litigation
Venture Funding Rounds
Strategic Corporate Investment
CTE Epidemiology
Sports Injury Liability

How this is made

Today For You My Stack Off Radar Search

Apellis Pharmaceuticals — company — Clarity Today

company

Apellis Pharmaceuticals

Waltham, MA immunology and rare-disease developer acquired by Biogen for up to $5.6 billion.

Known aliases

Apellis

Relationships

No evidence-backed relationships are recorded.

Current clusters

science1 distinct publisher

Massachusetts biotech: growth-stage money is back, seed money and NIH awards are not

MassBio's annual snapshot pairs a recovering VC, IPO and M&A market with a 39% fall in seed capital, a 6% drop in NIH awards and 3,605 lost jobs.

Publishers:genengnews.com

Reality

Evidence61
Adoption58
Hype gap+12
Incentives74

Confidence63